Long-term evolution of serum and liver viral markers in patients treated for chronic hepatitis C and sustained response
✍ Scribed by M. Moreno; R. Pérez-Alvarez; L. Rodrigo; R. Pérez-López; P. Suárez-Leiva
- Book ID
- 108885813
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 121 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1352-0504
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Our objective was to address two shortfalls in the hepatitis C virus (HCV) literature: (1) Few data exist comparing post-treatment liver-related mortality/morbidity in HCV-sustained virologic response (SVR) patients to non-SVR patients and (2) no data exist examining liver-related morbidity among tr
In the August 2011 issue of HEPATOLOGY, in the article entitled ''Carcinogen-induced hepatic tumors in KLF6þ/À mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation'' (volume 54, pages 522-531), Dr.
for the HALT-C Trial Group Chronic hepatitis C virus infection can cause chronic liver disease, cirrhosis and liver cancer. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial was a prospective, randomized controlled study of long-term, low-dose peginterferon therapy in pa